This website uses cookies to enhance the user experience.
||
HL

Haakon Lude Sande1978

Shareholdings
4
5
Norway Business roles
13

Roles

Management

NameRoleTotal operating incomeTotal equityShares
H
HALSA INVEST AS
Managing Director/CEO
-
1,161,922
100 %
directly
Managing Director/CEO
31,480,609
2,704,788
33.33 %
indirectly
S
SANDE HOLDING AS
Managing Director/CEO
4,887,000
6,700,197
33.33 %
indirectly
Z
ZERACRYL AS
Managing Director/CEO
128,744
2,632,983
6.27 %
indirectly
S
SANDE HOLDING AS
Closed
Managing Director/CEO
5,506,200
5,577,114
-

Boards

NameRoleTotal operating incomeTotal equityShares
H
HALSA INVEST AS
Chairman
-
1,161,922
100 %
directly
Board Member
31,480,609
2,704,788
33.33 %
indirectly
U
ULRIKSDAL 1 AS
Board Member
8,961,469
954,315
33.33 %
indirectly
C
CRUISESPESIALISTEN AS
Board Member
61,729,332
2,050,000
33.33 %
indirectly
S
SANDE HOLDING AS
Chairman
4,887,000
6,700,197
33.33 %
indirectly
Z
ZERACRYL AS
Board Member
128,744
2,632,983
6.27 %
indirectly
S
SANDE HOLDING AS
Closed
Chairman
5,506,200
5,577,114
-
D
DLS AS
Chairman
305,000
11,441,701
-
Last update: Sep 24, 2025

Shares owned by Haakon Lude Sande

NameShare classTotal operating incomeTotal equityShare
R
RECEIPTS AS
Ordinære aksjer
4,304,849
-1,006,306
0.7 %
directly 0.7 %
indirectly 0.62 %
H
HALSA INVEST AS
B-aksjer
A-aksjer
0
0
1,161,922
1,161,922
99.9 %
directly 100 %
0.1 %
directly 100 %
31,480,609
2,704,788
33.33 %
indirectly
U
ULRIKSDAL 1 AS
8,961,469
954,315
33.33 %
indirectly
C
CRUISESPESIALISTEN AS
61,729,332
2,050,000
33.33 %
indirectly
S
SANDE HOLDING AS
4,887,000
6,700,197
33.33 %
indirectly
Z
ZERACRYL AS
128,744
2,632,983
6.27 %
indirectly
I
IMMUNOPHARMA AS
NO0010735335
12,205,647,000
209,024,714,000
0.03 %
directly < 0.01 %

Limited to direct ownership positions of 0.5% or more.

Last update: Jun 2, 2025